Drug research

Ipilimumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as BMS-734016; Yervoy

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379	CytomX Therapeutics	Phase 2	Terminated	2020-05-21Actual
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219	Exelixis	Phase 3	Active not recruiting	2022-01-31Actual
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332	IDEAYA Biosciences	Phase 2, Phase 3	Active not recruiting	2027-01-15Estimated
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392	Immunocore Ltd	Phase 2	Completed	2020-10-13Actual
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928	IOVA	Phase 2	Terminated	2026-02-20Actual
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaNCT06581406	Replimune, Inc.	Phase 2, Phase 3	Recruiting	2030-01Estimated

CytomX TherapeuticsTerminatedPrimary completion: 2020-05-21 · Actual

Trial details

ExelixisActive not recruitingPrimary completion: 2022-01-31 · Actual

Trial details

IDEAYA BiosciencesActive not recruitingPrimary completion: 2027-01-15 · Estimated

Trial details

Immunocore LtdCompletedPrimary completion: 2020-10-13 · Actual

Trial details

IOVATerminatedPrimary completion: 2026-02-20 · Actual

Trial details

Replimune, Inc.RecruitingPrimary completion: 2030-01 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.